Nanolynx is developing conditionally active nanobody-drug conjugates that overcome the tissue penetration and toxicity limits of conventional ADCs, enabling safer and more efficacious therapies for hard-to-treat cancers.
Some insights
The team combines deep drug discovery and development expertise, AI/ML-driven platform building, antibody and nanobody engineering, and proven execution through clinic, partnerships, and fundraising. We plan to add senior clinical and regulatory capabilities as we scale.
